Compare RR & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RR | SIGA |
|---|---|---|
| Founded | 2016 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 483.0M | 401.0M |
| IPO Year | 2023 | 2016 |
| Metric | RR | SIGA |
|---|---|---|
| Price | $1.92 | $4.53 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 6.7M | 839.5K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 11.54% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.32 |
| Revenue | ★ $5,045,000.00 | N/A |
| Revenue This Year | $75.68 | N/A |
| Revenue Next Year | $78.28 | $224.81 |
| P/E Ratio | ★ N/A | $16.25 |
| Revenue Growth | ★ 18.99 | N/A |
| 52 Week Low | $1.69 | $4.81 |
| 52 Week High | $7.43 | $9.62 |
| Indicator | RR | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 34.57 | 29.68 |
| Support Level | $1.81 | N/A |
| Resistance Level | $2.04 | $6.98 |
| Average True Range (ATR) | 0.14 | 0.20 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 11.00 | 7.62 |
Richtech Robotics Inc is a robotics and artificial intelligence (AI) technology company focused on developing embodied AI systems that aims to improve the efficiency and productivity of businesses. The company trains proprietary artificial intelligence models on in-house data to operate robotic systems in the real world. It designs, engineers, manufactures, and deploys next generation embodied AI systems to serve a wide range of industries, including food service, retail, industrial manufacturing, automotive, healthcare, and hospitality. The company's offerings include Commercial Robotic Products, Industrial Robotic Products and Data Services. The company generated the majority of its revenue through product revenue (i.e. outright hardware sales).
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.